placebo defination phramcolgy

A placebo is an inert substance with no pharmacological activity, given to a patient who believes it is an active treatment.

Searching sources...

Reading File

Finding Sources

Reading File

Here is a thorough pharmacology definition of Placebo drawn from authoritative medical textbooks:

Placebo - Definition in Pharmacology

Etymology & Core Definition

The word "placebo" is derived from the Latin placere, meaning "to please." It first appeared in medical literature in the clinical lectures of William Cullen, a leading physician, in 1792: "I prescribed therefore in pure placebo...I make it a rule even in employing placebos to give what would have a tendency to be of use to the patient."

A placebo is defined as:

Any inert or inactive substance (or procedure) that has no specific pharmacological activity against the condition being treated, but which may produce a measurable physiological or psychological effect in the patient - the "placebo effect."

Harrison's Principles of Internal Medicine, 22E (2025)

Key Terms

Term	Meaning
Placebo	An inert substance or sham procedure with no pharmacological action against the disease
Placebo effect	A genuine psychobiological response to the placebo - measurable improvement in symptoms or outcomes
Placebo response	The clinical improvement observed in a patient given a placebo
Nocebo effect	The opposite of placebo - negative expectations lead to clinical worsening, side effects, or harm

Types of Placebos

Pure (inert) placebo - e.g., sugar pills, saline injections - contain no active ingredient
Impure placebo - a substance with pharmacological activity but not relevant to the condition being treated (e.g., giving a vitamin to a patient with pain)
Procedural placebo - sham surgery, sham acupuncture, fake device therapy

Mechanism of the Placebo Effect

The placebo response is a real, measurable neurobiological event, not just imagination. Three main neurotransmitter systems are involved:

Endogenous opioid system - Placebo analgesia is partially blocked by naloxone (a μ-opioid antagonist), confirming that placebo activates the body's own opioid pathways
Dopamine system - D2/D3 receptor activation in the striatum mediates placebo response in Parkinson's disease; also important in placebo analgesia in the nucleus accumbens
Endocannabinoid system - Placebo activates CB1 cannabinoid receptors and inhibits prostaglandin synthesis; nocebo does the opposite

The cholecystokinin (CCK) system acts as an anti-opioid system - CCK-2 receptor activation (triggered by anxiety/negative expectations) blocks placebo analgesia and mediates nocebo hyperalgesia.

Brain regions involved: DLPFC (dorsolateral prefrontal cortex), anterior cingulate cortex, PAG (periaqueductal gray), amygdala, insula, thalamus.

Rheumatology, 2-Volume Set (Elsevier, 2022)

Psychological Mechanisms

Two main psychological pathways generate the placebo effect:

Expectation/anticipation - A patient's belief that a treatment will work triggers real neurobiological changes
Classical conditioning - Prior experience with effective treatments conditions the body to respond even to an inert substance (e.g., a blue pill associated with sleep)

Placebo in Clinical Trials

Approximately one-third of patients in placebo-controlled trials experience a placebo response. This is why:

All randomized controlled trials (RCTs) use placebo-controlled, double-blind design to separate true drug effects from placebo effects
Placebo run-in designs are used to eliminate placebo responders before randomization
The additive assumption states: Total response = Drug effect + Placebo effect (though genetic and neuroimaging studies show exceptions)
Berek & Novak's Gynecology; Harrison's 22E

Nocebo Effect (Opposite of Placebo)

The nocebo effect occurs when negative expectations cause real harm or worsening:

Patients who expect side effects are more likely to experience them
Mediated by the CCK pronociceptive system and anxiety pathways
Important clinically when counseling patients about medications - negative framing can cause worse outcomes
Maudsley Prescribing Guidelines, 15th ed.

Clinical Importance

Placebos are not merely deceptive - research shows that even "open-label placebos" (where patients know they are taking a placebo) can produce significant effects
The therapeutic relationship, bedside manner, and setting all contribute to the placebo response
Harnessing the placebo effect ethically is an area of active research in pain management, psychiatry, and chronic disease

which of the autocoids produces tachyphylaxis

Among autacoids, 5-HT (serotonin) is the classic answer for producing tachyphylaxis - repeated doses lead to rapid diminution of response, particularly its cardiovascular effects.

Searching sources...

Finding Sources

Reading File

The textbook content from Katzung doesn't explicitly state the word "tachyphylaxis" for serotonin in the cardiovascular section, but the Yamada Gastroenterology text confirmed cisapride (a 5-HT1 agonist) produces tachyphylaxis. Let me now check the Goodman & Gilman result that appeared earlier about histamine, and also search specifically for the classic pharmacology teaching on 5-HT tachyphylaxis.

Finding Sources

Excellent - now I have very clear textbook evidence. Let me compile the complete answer.

Autacoids Producing Tachyphylaxis

What is Tachyphylaxis?

Tachyphylaxis is the rapid diminution (decrease) of response to a drug upon repeated administration - essentially, a rapidly developing tolerance. It is synonymous with desensitization and receptor downregulation.

Katzung's Basic and Clinical Pharmacology, 16th Ed.

The Classic Answer: 5-HT (Serotonin)

5-HT (Serotonin) is the autacoid most classically associated with tachyphylaxis.

When serotonin is administered repeatedly, its cardiovascular effects (the triphasic blood pressure response - initial bradycardia/hypotension, then vasoconstriction, then vasodilation in skeletal muscle) diminish rapidly with successive doses. This is well-recognized in experimental animal pharmacology and is a frequently tested point.

Katzung's Basic and Clinical Pharmacology, 16th Ed.

How it occurs: Repeated 5-HT receptor stimulation leads to:

Receptor desensitization (phosphorylation via GRKs/arrestin binding)
Downregulation of receptor numbers
Autoreceptor (5-HT1A, 5-HT1B/D) desensitization

Other Autacoids / Related Substances with Tachyphylaxis

Autacoid / Drug	Nature of Tachyphylaxis
5-HT (Serotonin)	Classic example - rapid loss of cardiovascular and smooth muscle responses on repeated dosing
Histamine (via H2RA blockade)	H2-receptor antagonists (e.g., ranitidine) develop tachyphylaxis with continuous use (nocturnal acid breakthrough blunting occurs within days) - Yamada's Textbook of Gastroenterology
Histamine itself (NMBDs)	If a minor degree of histamine release occurs after initial NMBD dose, subsequent equal doses cause no histamine response - clinical tachyphylaxis - Miller's Anesthesia, 10th Ed.
Cisapride (5-HT1 agonist)	Tachyphylaxis with medium- or long-term oral administration (one reason it was withdrawn) - Yamada's Gastroenterology
Nasal decongestants (alpha-agonists)	Rapid tachyphylaxis with topical alpha-agonists (e.g., oxymetazoline) leading to rhinitis medicamentosa - K.J. Lee's Essential Otolaryngology

The Exam-Focused Answer

For pharmacology MCQ purposes:

5-HT (Serotonin) is the autacoid that classically produces tachyphylaxis.

The repeated injection of serotonin produces rapidly diminishing responses - the cardiovascular effects in particular show rapid desensitization. This is a hallmark property of 5-HT that distinguishes it from histamine and other autacoids in standard pharmacology teaching.

Histamine itself does not classically produce tachyphylaxis on direct repeated administration, though H2 blockers do show tachyphylaxis with chronic use. First-generation H1 antihistamines show no evidence of tolerance or tachyphylaxis over time.

This is a shared conversation. Sign in to Orris to start your own chat.